Complex generic drug sponsors now can track the US Food and Drug Administration's plans for new and revised product-specific guidances and potentially avoid development or application assessment setbacks.
However, like the agency’s other guidance agendas, in many cases product-specific guidances (PSGs) have remained listed as upcoming or due for revision across several plan updates, clouding the time publication...